Apogenix GmbH Company Profile
The biopharmaceutical company Apogenix, located in Heidelberg, Germany, develops innovative drug candidates which exert their therapeutic effect by modulating the programmed cell death (apoptosis). The therapeutic focus lies on acute cerebro- and cardiovascular diseases (e.g. myocardial infarction) where apoptosis is abnormally increased, and on cancer diseases where apoptosis is abnormally decreased.Apogenix was founded as a spin-out of the German Cancer Research Center (Heidelberg, Germany) by Prof. Peter Krammer and Dr. Henning Walczak in 2000. The company started its operative business in May 2002 as Apogenix Biotechnology AG. Until the end of 2004, therapeutic efficacy of an apoptosis-inhibitor was shown in a variety of animal models (e.g. myocardial infarction, graft-versus-host-disease, stroke). In the context of a financial and organizational restructuring of the company and with the support of private investors, the essential assets were transferred to the newly founded Apogenix GmbH.
Today´s management board members are Dr. Thomas Höger and Dr. Harald Fricke, both having extensive industry experience. Apogenix GmbH is funded by the family of Dietmar Hopp, one of the SAP founders. The family has committed EUR 15m for the (pre)clinical development of the above mentioned apoptosis inhibitor and further drug candidates. Currently, Apogenix occupies about 740m² laboratory and office space in the Technology Park Heidelberg.
Im Neuenheimer Feld 584
Die Heidelberger Apogenix GmbH hat für eine Phase II-Studie mit dem Krebswirkstoff APG101 die...
As Apogenix announced the figures that confirm that the primary objective of its Phase II proof-of-concept trial investigating its lead product, APG101, as a second line treatment of glioblastoma mult...
Clinical stage biopharmaceutical company Apogenix's Apocept (APG101) has won FDA orphan drug designation to treat myelodysplastic syndromes (MDS).
- Primary endpoint of PFS6 shows significant improvement - PFS median P-value: 0.0114 - Positive results confirmed by secondary endpoints Heidelberg, Germany, July 26, 2012 - The biopharmaceutical com...
- Primary endpoint of PFS6 shows significant improvement - PFS median P-value: 0.0114 - Positive results confirmed by secondary endpoints HEIDELBERG, Germany--(BUSINESS WIRE)--Jul 26, 2012 - The bioph...
The FDA granted orphan-drug status to Apocept, or APG101, Apogenix's investigational drug for myelodysplastic syndromes. -More-
Primary endpoint of PFS6 shows significant improvement PFS median P-value: 0.0114 Positive results confirmed by secondary endpoints
Drugs and Medications
The biopharmaceutical company Apogenix, located in Heidelberg, Germany, develops innovative drug candidates which exert their therapeutic effect by modulating the programmed cell death (apoptosis). Th...
More Information about "Apogenix GmbH" on BioPortfolio
We have published hundreds of Apogenix GmbH news stories on BioPortfolio along with dozens of Apogenix GmbH Clinical Trials and PubMed Articles about Apogenix GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Apogenix GmbH Companies in our database. You can also find out about relevant Apogenix GmbH Drugs and Medications on this site too.